The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

At the oncology segment, the drugmaker's biggest therapy area, revenue grew 22% at constant currencies to $5.57 billion, helped by demand for its blockbuster drugs Imfinzi, Tagrisso and Calquence.

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

The guidance hike followed forecast-beating third quarter results, with revenues up 21% on a constant currency basis to 13.57 ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...

Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.